Literature DB >> 17823253

The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5.

Julie C Crockett1, Norbert Schütze, Denise Tosh, Susanne Jatzke, Angela Duthie, Franz Jakob, Michael J Rogers.   

Abstract

Cysteine-rich protein 61 (CYR61/CCN1) belongs to the family of CCN matricellular proteins. Most of the known effects of CCN proteins appear to be due to binding to extracellular growth factors or integrins, including alpha(v)beta(3) and alpha(v)beta(5). Although CYR61 can stimulate osteoblast differentiation, until now the effect of CYR61 on osteoclasts was unknown. We demonstrate that recombinant human CYR61 inhibits the formation of multinucleated, alpha(v)beta(3)-positive, or tartrate-resistant acid phosphatase-positive human, mouse, and rabbit osteoclasts in vitro. CYR61 markedly reduced the expression of the osteoclast phenotypic markers tartrate-resistant acid phosphatase, matrix metalloproteinase-9, calcitonin receptor, and cathepsin K. However, CYR61 did not affect the formation of multinucleated osteoclasts when added to osteoclast precursors prior to fusion or affect the number or resorptive activity of osteoclasts cultured on dentine discs, indicating that CYR61 affects early osteoclast precursors but not mature osteoclasts. CYR61 did not affect receptor activator of nuclear factor-kappaB (RANK) ligand-induced phosphorylation of p38 or ERK1/2 in human macrophages and did not affect RANK ligand-induced activation of nuclear factor-kappaB, indicating that CYR61 does not appear to inhibit osteoclastogenesis by affecting RANK signaling. Furthermore, a mutant form of CYR61 defective in binding to alpha(v)beta(3) also inhibited osteoclastogenesis, and CYR61 inhibited osteoclastogenesis similarly in cultures of mouse wild-type or beta(5)(-/-) macrophages. Thus, CYR61 does not appear to inhibit osteoclast formation by interacting with alpha(v)beta(3) or alpha(v)beta(5). These observations demonstrate that CYR61 is a hitherto unrecognized inhibitor of osteoclast formation, although the exact mechanism of inhibition remains to be determined. Given that CYR61 also stimulates osteoblasts, CYR61 could represent an important bifunctional local regulator of bone remodeling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823253     DOI: 10.1210/en.2007-0473

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  26 in total

Review 1.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

2.  CCN family 2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via induction of and interaction with dendritic cell-specific transmembrane protein (DC-STAMP).

Authors:  Takashi Nishida; Kenji Emura; Satoshi Kubota; Karen M Lyons; Masaharu Takigawa
Journal:  J Bone Miner Res       Date:  2011-02       Impact factor: 6.741

3.  Microcracks and osteoclast resorption activity in vitro.

Authors:  Monika Rumpler; Tanja Würger; Paul Roschger; Elisabeth Zwettler; Herwig Peterlik; Peter Fratzl; Klaus Klaushofer
Journal:  Calcif Tissue Int       Date:  2012-01-24       Impact factor: 4.333

4.  YAP and TAZ Mediate Osteocyte Perilacunar/Canalicular Remodeling.

Authors:  Christopher D Kegelman; Jennifer C Coulombe; Kelsey M Jordan; Daniel J Horan; Ling Qin; Alexander G Robling; Virginia L Ferguson; Teresita M Bellido; Joel D Boerckel
Journal:  J Bone Miner Res       Date:  2019-10-14       Impact factor: 6.741

5.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

Review 6.  CCN1/CYR61: the very model of a modern matricellular protein.

Authors:  Lester F Lau
Journal:  Cell Mol Life Sci       Date:  2011-07-31       Impact factor: 9.261

7.  Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.

Authors:  Afak Rasheed Salman Zaidi; Sadie Dresman; Charlotte Burt; Simon Rule; Lynn McCallum
Journal:  J Cell Commun Signal       Date:  2018-11-21       Impact factor: 5.782

Review 8.  Matricellular protein CCN1/CYR61: a new player in inflammation and leukocyte trafficking.

Authors:  Yalin Emre; Beat A Imhof
Journal:  Semin Immunopathol       Date:  2014-03-18       Impact factor: 9.623

9.  Nephroblastoma overexpressed (Nov) inactivation sensitizes osteoblasts to bone morphogenetic protein-2, but nov is dispensable for skeletal homeostasis.

Authors:  Ernesto Canalis; Anna Smerdel-Ramoya; Deena Durant; Aris N Economides; Wesley G Beamer; Stefano Zanotti
Journal:  Endocrinology       Date:  2009-11-24       Impact factor: 4.736

10.  Osteoblast-released Matrix Vesicles, Regulation of Activity and Composition by Sulfated and Non-sulfated Glycosaminoglycans.

Authors:  Johannes R Schmidt; Stefanie Kliemt; Carolin Preissler; Stephanie Moeller; Martin von Bergen; Ute Hempel; Stefan Kalkhof
Journal:  Mol Cell Proteomics       Date:  2015-11-23       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.